Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...

Roche (ROG.SW) and Zealand Pharma (ZEAL.CO) stocks are in focus after the company announced an agreement to make amylin, an obesity drug, in a deal valued at $5.3 billion. Yahoo Finance Senior ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...